VANCOUVER, British Columbia, March 09, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update and reported financial results for the year ending December 31, 2016.
“We are actively enrolling patients in the LEADERSHIP 301 Phase 3 clinical trial with AQX-1125 in interstitial cystitis/bladder pain syndrome (IC/BPS) and are encouraged by initiated sites enrolling patients at the expected pace,” said David Main, President & CEO of Aquinox. “However, the rate of initiating sites has been considerably slower than planned such that we now expect top-line data in 2018. With enrollment accelerating, sites continuing to be added and recruitment optimization plans underway for initiated sites, we anticipate having a clearer outlook on timing of top-line data at our mid-year financial call in August.”
“We are actively enrolling patients in the LEADERSHIP 301 Phase 3 clinical trial with AQX-1125 in interstitial cystitis/bladder pain syndrome (IC/BPS) and are encouraged by initiated sites enrolling patients at the expected pace,” said David Main, President & CEO of Aquinox. “However, the rate of initiating sites has been considerably slower than planned such that we now expect top-line data in 2018. With enrollment accelerating, sites continuing to be added and recruitment optimization plans underway for initiated sites, we anticipate having a clearer outlook on timing of top-line data at our mid-year financial call in August.”
